Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
P/B ratio for Prothena Corporation plc (PRTA)
P/B ratio as of 2023: 3.44
According to Prothena Corporation plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.44. At the end of 2022 the company had a P/B ratio of 4.59.
P/B ratio history for Prothena Corporation plc from 2010 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.44 |
| 2022 | 4.59 |
| 2021 | 4.69 |
| 2020 | 2.61 |
| 2019 | 2.31 |
| 2018 | 1.26 |
| 2017 | 3.47 |
| 2016 | 4.62 |
| 2015 | 5.73 |
| 2014 | 1.77 |
| 2013 | 2.85 |
| 2012 | 0.85 |
| 2011 | -19.78 |
| 2010 | 0.00 |